ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Recurrence
Cancer
Hematologic Cancer
Non-Hodgkin Lymphoma
Lymphoma
Smoldering Multiple Myeloma

Multiple Myeloma trials near Kansas City, KS, USA:

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Westwood, Kansas, United States and 59 other locations

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Kansas City, Kansas, United States and 68 other locations

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)

phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Westwood, Kansas, United States and 29 other locations

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Kansas City, Missouri, United States and 211 other locations

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Biological: Arlocabtagene Autoleucel

Phase 2

Juno Therapeutics

Westwood, Kansas, United States and 51 other locations

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM12)

antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Westwood, Kansas, United States and 18 other locations

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma...

Active, not recruiting
Multiple Myeloma
Drug: CC-220
Drug: Bortezomib (BTZ)

Phase 1, Phase 2

Celgene
Celgene

Fairway, Kansas, United States and 161 other locations

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Bortezomib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Kansas City, Missouri, United States and 118 other locations

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Kansas City, Missouri, United States and 265 other locations

Locations recently updated

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the t...

Enrolling
Multiple Myeloma
Drug: Pomalidomide
Drug: Elotuzumab

Phase 3

Pfizer
Pfizer

Kansas City, Missouri, United States and 127 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems